UroGen Pharma Ltd — Balance Sheet (NASDAQ:URGN) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics

Quarterly Annual

Total assets 122 M119.75 M135.62 M178.31 M285.71 M200.46 M Total liabilities 25.65 M111.33 M224.98 M243.52 M294.51 M305.93 M Total equity 96.36 M8.41 M-89.36 M-65.21 M-8.8 M-105.47 M Total liabilities & shareholders' equities 122 M119.75 M135.62 M178.31 M285.71 M200.46 M Total debt ——97.54 M98.55 M122.48 M123.48 M Net debt ——-2.43 M-42.95 M-119.22 M2.98 M

Haberler

UroGen’in Zusduri ilacı 24 ayda %72 olay-sız kalma oranı gösterdi

UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers

UroGen Pharma TD Cowen Konferansı’nda büyüme stratejisini açıkladı

UroGen Pharma at TD Cowen Conference: Strategic Growth and Innovation

Oppenheimer, UroGen Pharma hissesi için hedef fiyatı Zusduri satışları nedeniyle 34 dolara yükseltti

Oppenheimer raises UroGen Pharma stock price target to $34 on Zusduri sales

Oppenheimer güçlü Zusduri satışları sonrası UroGen hissesi için hedef tekrarladı

Oppenheimer reiterates UroGen Pharma stock rating on strong Zusduri sales

UroGen Pharma 4Ç 2025 sonuçları beklentileri karşılamadı

Earnings call transcript: UroGen Pharma Q4 2025 misses EPS and revenue forecasts

Palantir and AeroVironment among market cap stock movers on Monday

Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates